Drug General Information
Drug ID
D07QAR
Former ID
DCL000512
Drug Name
Dalbavancin
Synonyms
Zeven; Zeven (TN); Dalbavancin (USAN/INN)
Drug Type
Small molecular drug
Indication Bacterial infections [ICD9: 001-009, 010-018, 020-027, 030-041, 080-088, 090-099, 100-104; ICD10:A00-B99] Approved [533123], [551871]
Company
Pfizer
Structure
Download
2D MOL

3D MOL

Formula
C88H100Cl2N10O28
Canonical SMILES
CC(C)CCCCCCCCC(=O)NC1C(C(C(OC1OC2=C3C=C4C=C2OC5=C(C=C(C<br />=C5)C(C6C(=O)NC(C7=CC(=CC(=C7C8=C(C=CC(=C8)C(C(=O)N6)NC<br />(=O)C4NC(=O)C9C1=CC(=CC(=C1Cl)O)OC1=C(C=CC(=C1)C(C(=O)N<br />C(CC1=CC=C(O3)C=C1)C(=O)N9)NC)O)O)OC1C(C(C(C(O1)CO)O)O)<br />O)O)C(=O)NCCCN(C)C)O)Cl)C(=O)O)O)O
InChI
1S/C88H100Cl2N10O28/c1-38(2)13-10-8-6-7-9-11-14-61(106)94-70-73(109)75(111)78(86(120)121)128-87(70)127-77-58-31-43-32-59(77)124-55-24-19-42(29-50(55)89)71(107)69-85(119)98-67(80(114)92-25-12-26-100(4)5)48-33-44(102)34-57(125-88-76(112)74(110)72(108)60(37-101)126-88)62(48)47-28-40(17-22-52(47)103)65(82(116)99-69)95-83(117)66(43)96-84(118)68-49-35-46(36-54(105)63(49)90)123-56-30-41(18-23-53(56)104)64(91-3)81(115)93-51(79(113)97-68)27-39-15-20-45(122-58)21-16-39/h15-24,28-36,38,51,60,64-76,78,87-88,91,101-105,107-112H,6-14,25-27,37H2,1-5H3,(H,92,114)(H,93,115)(H,94,106)(H,95,117)(H,96,118)(H,97,113)(H,98,119)(H,99,116)(H,120,121)/t51-,60-,64-,65-,66-,67?,68+,69+,70-,71-,72-,73-,74+,75+,76+,78+,87-,88+/m1/s1
InChIKey
KGPGQDLTDHGEGT-VBZOGQDBSA-N
CAS Number
CAS 91097-81-3
PubChem Compound ID
PubChem Substance ID
SuperDrug ATC ID
J01XA04
Target and Pathway
Target(s) Triacylglycerol lipase, pancreatic Target Info Inhibitor [536589], [549974]
BioCyc Pathway Triacylglycerol degradation
Retinol biosynthesis
KEGG Pathway Glycerolipid metabolism
Metabolic pathways
Pancreatic secretion
Fat digestion and absorption
Vitamin digestion and absorption
Reactome Retinoid metabolism and transport
WikiPathways Visual phototransduction
Lipid digestion, mobilization, and transport
References
Ref 5331232014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
Ref 551871Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 536589Dalbavancin: a novel once-weekly lipoglycopeptide antibiotic. Clin Infect Dis. 2008 Feb 15;46(4):577-83.
Ref 549974Pfizer. Product Development Pipeline. March 31 2009.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.